Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Proteomic Characterisation of the Plasma Proteome in Extramedullary Multiple Myeloma Identifies Potential Prognostic Biomarkers

Katie Dunphy, Despina Bazou, Paul Dowling, Peter O'Gorman

Blood (2022) 140 (Supplement 1): 10058–10059.

https://doi.org/10.1182/blood-2022-159935

Published: 2022

Journal Articles

Targeted Metabolomics Approach Identifies Alterations in the Plasma Metabolome of Multiple Myeloma Patients with and without Extramedullary Spread

Katie Dunphy, Despina Bazou, Paul Dowling, Peter O'Gorman

Blood (2022) 140 (Supplement 1): 4328–4329.

https://doi.org/10.1182/blood-2022-160198

Published: 2022

Journal Articles

Phosphoproteomic Analysis of Primary Myeloma Patient Samples Identifies Distinct Phosphorylation Signatures Correlating with Chemo-Sensitivity Profiles in an Ex Vivo Drug Sensitivity Testing Platform

Katie Dunphy, Paul Dowling, Juho J. Miettinen, Caroline A. Heckman, Paula Meleady, Michael Henry, Despina Bazou, Peter O'Gorman

Blood (2021) 138 (Supplement 1): 2666.

https://doi.org/10.1182/blood-2021-148382

Published: 2021

Journal Articles

Characterisation of the Tumour Proteome in Primary Extramedullary Multiple Myeloma Identifies Key Proteins Associated with Transendothelial Migration

Katie Dunphy, Despina Bazou, Michael Henry, Paula Meleady, Paul Dowling, Peter O'Gorman

Blood (2021) 138 (Supplement 1): 2665.

https://doi.org/10.1182/blood-2021-152676

Published: 2021

Journal Articles

Multi-Parametric Single Cell Profiling Defines Distinct Drug Responses in Healthy Hematological Cell Lineages That Are Retained in Corresponding Malignant Cell Types

Muntasir M Majumder, MSc, BPharm, Maija Leppä, MSc(Tech), Monica Hellesoy, PhD, Paul Dowling, BSc, PhD, Alina Malyutina, Despina Bazou, BSc, MSc, PhD, Emma Irene Andersson, MSc, Alun Parsons, Jing Tang, PhD, Olli Kallioniemi, MD PhD, Satu Mustjoki, MDPhD, Peter O'Gorman, MD PhD FRCP, FRCPath, Krister Wennerberg, PhD, Kimmo Porkka, MD PhD, Bjorn Gjertsen, MD PhD, Caroline A Heckman, PhD

Blood (2018) 132 (Supplement 1): 264.

https://doi.org/10.1182/blood-2018-99-118242

Published: 2018

Journal Articles

Combining Next Generation Proteomics Platforms with Drug Sensitivity Resistance Testing AllowsÂ Identification of Physiologically Distinct Sub-ClonesÂ That Can Inform Therapeutic and Drug Development Strategies

Despina Bazou, BSc, MSc, PhD, Muntasir M Majumder, MSc, BPharm, Ciara Tierney, BSc, Sinead O'Rourke, BSc, Pekka Anttila, MD, Raija Helena Silvennoinen, MD PhD, Caroline A Heckman, PhD, Paul Dowling, BSc, PhD, Peter O'Gorman, MD PhD FRCP, FRCPath

Blood (2018) 132 (Supplement 1): 1901.

https://doi.org/10.1182/blood-2018-99-115910

Published: 2018

Journal Articles

Saliva-Omics in Plasma Cell Disorders — Proof of Concept and Potential As a Non-Invasive Tool for Monitoring Disease Burden and MRD Status

Ciara Tierney, BSc, Despina Bazou, BSc, MSc, PhD, Giao Le, BA (Hons), MB BCh, MRCPI, Paul Dowling, BSc, PhD, Peter O'Gorman, MD PhD FRCP, FRCPath

Blood (2018) 132 (Supplement 1): 3177.

https://doi.org/10.1182/blood-2018-99-110166

Published: 2018

NARROW

Proteomic Characterisation of the Plasma Proteome in Extramedullary Multiple Myeloma Identifies Potential Prognostic Biomarkers

Targeted Metabolomics Approach Identifies Alterations in the Plasma Metabolome of Multiple Myeloma Patients with and without Extramedullary Spread

Phosphoproteomic Analysis of Primary Myeloma Patient Samples Identifies Distinct Phosphorylation Signatures Correlating with Chemo-Sensitivity Profiles in an Ex Vivo Drug Sensitivity Testing Platform

Characterisation of the Tumour Proteome in Primary Extramedullary Multiple Myeloma Identifies Key Proteins Associated with Transendothelial Migration

Multi-Parametric Single Cell Profiling Defines Distinct Drug Responses in Healthy Hematological Cell Lineages That Are Retained in Corresponding Malignant Cell Types

Combining Next Generation Proteomics Platforms with Drug Sensitivity Resistance Testing AllowsÂ Identification of Physiologically Distinct Sub-ClonesÂ That Can Inform Therapeutic and Drug Development Strategies

Saliva-Omics in Plasma Cell Disorders — Proof of Concept and Potential As a Non-Invasive Tool for Monitoring Disease Burden and MRD Status

Email alerts

ASH Publications

American Society of Hematology

Proteomic Characterisation of the Plasma Proteome in Extramedullary Multiple Myeloma Identifies Potential Prognostic Biomarkers

Targeted Metabolomics Approach Identifies Alterations in the Plasma Metabolome of Multiple Myeloma Patients with and without Extramedullary Spread

Phosphoproteomic Analysis of Primary Myeloma Patient Samples Identifies Distinct Phosphorylation Signatures Correlating with Chemo-Sensitivity Profiles in an Ex Vivo Drug Sensitivity Testing Platform

Characterisation of the Tumour Proteome in Primary Extramedullary Multiple Myeloma Identifies Key Proteins Associated with Transendothelial Migration

Multi-Parametric Single Cell Profiling Defines Distinct Drug Responses in Healthy Hematological Cell Lineages That Are Retained in Corresponding Malignant Cell Types

Combining Next Generation Proteomics Platforms with Drug Sensitivity Resistance Testing AllowsÂ Identification of Physiologically Distinct Sub-ClonesÂ That Can Inform Therapeutic and Drug Development Strategies

Saliva-Omics in Plasma Cell Disorders — Proof of Concept and Potential As a Non-Invasive Tool for Monitoring Disease Burden and MRD Status

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only